Genetic Testing

Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024

Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024

SALT LAKE CITY, July 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and…

9 months ago
CORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics SummitCORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit

CORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit

- This Version Removes the Use of 'Presentation' from the Prior-issued Headline -- Linea™ IVT Platform Delivers All The Benefits…

9 months ago
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Presentation Annual mRNA-based Therapeutics SummitApplied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Presentation Annual mRNA-based Therapeutics Summit

Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Presentation Annual mRNA-based Therapeutics Summit

- Linea™ IVT Platform Delivers All The Benefits of Conventional IVT Without dsRNA Contamination - STONY BROOK, NY / ACCESSWIRE…

9 months ago
Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic CystsInterpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts

Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts

PARSIPPANY, NJ, July 29, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX:…

9 months ago
Genetic Technologies Strategic Restructure Driving USA Sales GrowthGenetic Technologies Strategic Restructure Driving USA Sales Growth

Genetic Technologies Strategic Restructure Driving USA Sales Growth

CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader…

10 months ago
Applied DNA Enters into Multi-Year Commercialization Agreement with Indus Group for Large-Scale Implementation of CertainT Cotton TraceabilityApplied DNA Enters into Multi-Year Commercialization Agreement with Indus Group for Large-Scale Implementation of CertainT Cotton Traceability

Applied DNA Enters into Multi-Year Commercialization Agreement with Indus Group for Large-Scale Implementation of CertainT Cotton Traceability

- Indus Group Consumes Approximately 450 Million Pounds of Cotton Annually for the Manufacture of Apparel, Footwear, and Accessories for…

10 months ago
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic ObesityRhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity

Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity

-- LB54640 has shown targeted effect on MC4R without hyperpigmentation -- BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc.…

10 months ago
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the…

10 months ago
U.S. Defense Logistics Agency Exercises 1-Year Option Period in  Applied DNA Counterfeit Mitigation ContractU.S. Defense Logistics Agency Exercises 1-Year Option Period in  Applied DNA Counterfeit Mitigation Contract

U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract

STONY BROOK, NY / ACCESSWIRE / July 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in…

10 months ago
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer RiskWhat We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk

What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk

New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased…

10 months ago